These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 7191065)

  • 21. Tolerance to the effects of baclofen and gamma-butyrolactone on locomotor activity and dopaminergic neurons in the mouse.
    Gianutsos G; Moore KE
    J Pharmacol Exp Ther; 1978 Dec; 207(3):859-69. PubMed ID: 731436
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of fentanyl and droperidol on the dopamine metabolism of the rat striatum.
    Freye E; Kuschinsky K
    Pharmacology; 1976; 14(1):1-7. PubMed ID: 986654
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of naloxone on dopamine uptake and release in vitro in the striatum.
    Feigenbaum JJ; Yanai J; Iser C; Klawans H
    Neuropsychobiology; 1984; 11(2):94-7. PubMed ID: 6483167
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structure-activity relationships of alkyl-substituted gamma-butyrolactones and succinimides.
    Klunk WE; Covey DF; Ferrendelli JA
    Mol Pharmacol; 1982 Sep; 22(2):444-50. PubMed ID: 7144737
    [No Abstract]   [Full Text] [Related]  

  • 25. Opiate-receptor mediated changes in monoamine synthesis in rat brain.
    Garcia-Sevilla JA; Ahtee L; Magnusson T; Carlsson A
    J Pharm Pharmacol; 1978 Oct; 30(10):613-21. PubMed ID: 30814
    [No Abstract]   [Full Text] [Related]  

  • 26. Role of striatal dopaminergic receptors in amphetamine-induced behavioral facilitation.
    Conway PG; Uretsky NJ
    J Pharmacol Exp Ther; 1982 Jun; 221(3):650-5. PubMed ID: 7201019
    [No Abstract]   [Full Text] [Related]  

  • 27. Transmitter metabolism in substantia nigra after inhibition of dopaminergic neurones by butyrolactone.
    Hefti F; Lienhart R; Lichtensteiger W
    Nature; 1976 Sep; 263(5575):341-3. PubMed ID: 958491
    [No Abstract]   [Full Text] [Related]  

  • 28. Chronic gamma-butyrolactone (GBL) treatment: a potential model of dopamine hypoactivity.
    Nowycky MC; Roth RH
    Naunyn Schmiedebergs Arch Pharmacol; 1979 Nov; 309(3):247-54. PubMed ID: 43476
    [No Abstract]   [Full Text] [Related]  

  • 29. Comparison of epileptogenic properties of unsubstituted and beta-alkyl-substituted gamma-butyrolactones.
    Klunk WE; Covey DF; Ferrendelli JA
    Mol Pharmacol; 1982 Sep; 22(2):431-7. PubMed ID: 7144735
    [No Abstract]   [Full Text] [Related]  

  • 30. gamma-Butyrolactone effects on behavior induced by dopamine agonists.
    Ellinwood EH; Gonzalez AE; Dougherty GG
    Biol Psychiatry; 1983 Sep; 18(9):1023-32. PubMed ID: 6685535
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Supersensitivity to the behavioral effects of opiate antagonists [proceedings].
    Spealman RD; Kelleher RT; Morse WH; Goldberg SR
    Psychopharmacol Bull; 1981 Jan; 17(1):54-6. PubMed ID: 7232659
    [No Abstract]   [Full Text] [Related]  

  • 32. Subcellular distribution of dopamine in substantia nigra of the rat brain: effects of gamma-butyrolactone and destruction of noradrenergic afferents suggest formation of particles from dendrites.
    Hefti F; Lichtensteiger W
    J Neurochem; 1978 Jun; 30(6):1217-30. PubMed ID: 209130
    [No Abstract]   [Full Text] [Related]  

  • 33. Anticonvulsant properties of alpha, gamma, and alpha, gamma-substituted gamma-butyrolactones.
    Klunk WE; Covey DF; Ferrendelli JA
    Mol Pharmacol; 1982 Sep; 22(2):438-43. PubMed ID: 7144736
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Naloxone elicits dose-dependent changes in alcohol-induced increases in endogenous dopamine release from rat striatum.
    Holman RB; Snape BM; Widdowson PS
    Alcohol Alcohol Suppl; 1987; 1():737-41. PubMed ID: 3426755
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Action of beta(4-chlorphenyl)GABA, gamma-hydroxybutyrolactone, and apomorphine on central dopamine neurons.
    Fuxe K; Agnati L; Everitt BJ; Hökfelt T; Ljungdahl A; Perez de la Mora M
    Adv Biochem Psychopharmacol; 1977; 16():489-94. PubMed ID: 883553
    [No Abstract]   [Full Text] [Related]  

  • 36. The effects of endomorphins and diprotin A on striatal dopamine release induced by electrical stimulation-an in vitro superfusion study in rats.
    Bagosi Z; Jászberényi M; Bujdosó E; Szabó G; Telegdy G
    Neurochem Int; 2006 Dec; 49(7):665-8. PubMed ID: 16815593
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: II. Both D2 and "silent" D3 autoreceptors control synthesis and release in mesolimbic, mesocortical and nigrostriatal pathways.
    Gobert A; Rivet JM; Audinot V; Cistarelli L; Spedding M; Vian J; Peglion JL; Millan MJ
    J Pharmacol Exp Ther; 1995 Nov; 275(2):899-913. PubMed ID: 7473181
    [TBL] [Abstract][Full Text] [Related]  

  • 38. EEG and other effects of naltrexone and heroin in man.
    Volavka J; James B; Reker D; Mallya A; Cho D; Pevnick J
    Pharmakopsychiatr Neuropsychopharmakol; 1979 Jan; 12(1):79-85. PubMed ID: 570272
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interactions between D1 and D2 dopamine receptor family agonists and antagonists: the effects of chronic exposure on behavior and receptor binding in rats and their clinical implications.
    Braun AR; Laruelle M; Mouradian MM
    J Neural Transm (Vienna); 1997; 104(4-5):341-62. PubMed ID: 9295170
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Naltrexone modulates dopamine release following chronic, but not acute amphetamine administration: a translational study.
    Jayaram-Lindström N; Guterstam J; Häggkvist J; Ericson M; Malmlöf T; Schilström B; Halldin C; Cervenka S; Saijo T; Nordström AL; Franck J
    Transl Psychiatry; 2017 Apr; 7(4):e1104. PubMed ID: 28440810
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.